Published in Int J Tuberc Lung Dis on November 01, 2004
SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Antimicrob Agents Chemother (2012) 2.41
Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob Agents Chemother (2006) 2.35
An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future. Antimicrob Agents Chemother (2010) 1.71
Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes. Antimicrob Agents Chemother (2009) 1.36
Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action. Future Microbiol (2012) 1.27
Low levels of pyrazinamide and ethambutol in children with tuberculosis and impact of age, nutritional status, and human immunodeficiency virus infection. Antimicrob Agents Chemother (2006) 1.25
Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines. Antimicrob Agents Chemother (2012) 1.04
Ethambutol optimal clinical dose and susceptibility breakpoint identification by use of a novel pharmacokinetic-pharmacodynamic model of disseminated intracellular Mycobacterium avium. Antimicrob Agents Chemother (2010) 1.04
Ethambutol pharmacokinetic variability is linked to body mass in overweight, obese, and extremely obese people. Antimicrob Agents Chemother (2011) 0.97
Population pharmacokinetics of ethambutol in South African tuberculosis patients. Antimicrob Agents Chemother (2011) 0.95
A metabolic biosignature of early response to anti-tuberculosis treatment. BMC Infect Dis (2014) 0.92
Interaction of Ethambutol with human organic cation transporters of the SLC22 family indicates potential for drug-drug interactions during antituberculosis therapy. Antimicrob Agents Chemother (2013) 0.84
Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in Indian children. BMC Infect Dis (2015) 0.81
Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring. Eur J Clin Pharmacol (2016) 0.80
Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines. Antimicrob Agents Chemother (2016) 0.77
Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Newly Diagnosed Pulmonary TB Patients in Tanzania. PLoS One (2015) 0.76
hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell (1997) 8.74
Design and validation of a tool for neurite tracing and analysis in fluorescence microscopy images. Cytometry A (2004) 8.65
Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med (1998) 3.64
Usefulness of the secondary probe pTBN12 in DNA fingerprinting of Mycobacterium tuberculosis. J Clin Microbiol (1996) 2.91
Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis (2006) 2.83
A critical review of diagnostic approaches used in the diagnosis of childhood tuberculosis. Int J Tuberc Lung Dis (2002) 2.73
Letter: Creatinine clearance: bedside estimate. Ann Intern Med (1973) 2.52
Differential modulation of cyclin gene expression by MYC. Proc Natl Acad Sci U S A (1993) 2.31
Acute isoniazid neurotoxicity in an urban hospital. Pediatrics (1995) 2.28
Pulmonary tuberculosis in AIDS patients: transient chest radiographic worsening after initiation of antiretroviral therapy. AJR Am J Roentgenol (2000) 2.20
An improved method of digoxin therapy. Ann Intern Med (1968) 2.19
Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. Antimicrob Agents Chemother (1997) 2.13
Use of rifabutin with protease inhibitors for human immunodeficiency virus-infected patients with tuberculosis. Clin Infect Dis (2000) 2.08
Tuberculosis recurrence: multivariate analysis of serum levels of tuberculosis drugs, human immunodeficiency virus status, and other risk factors. Clin Infect Dis (2001) 2.03
Epidemiology of Pneumocystis carinii pneumonia in an era of effective prophylaxis: the relative contribution of non-adherence and drug failure. AIDS (2000) 1.97
Treatment experience of multidrug-resistant tuberculosis in Florida, 1994-1997. Chest (2001) 1.91
Low antituberculosis drug concentrations in patients with AIDS. Ann Pharmacother (1996) 1.86
Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med (1998) 1.85
Clinical features, diagnosis, and treatment of tuberculosis in infants. Pediatrics (1994) 1.83
Persistently negative tuberculin reactions: their presence among children with culture positive for Mycobacterium tuberculosis (tuberculin-negative tuberculosis). Am J Dis Child (1980) 1.78
Gastric lavage is better than bronchoalveolar lavage for isolation of Mycobacterium tuberculosis in childhood pulmonary tuberculosis. Pediatr Infect Dis J (1992) 1.66
Multi-laboratory comparison of three heparin-Mn2+ precipitation procedures for estimating cholesterol in high-density lipoprotein. Clin Chem (1978) 1.63
Detection of Bordetella pertussis associated with the alveolar macrophages of children with human immunodeficiency virus infection. Infect Immun (1991) 1.62
Estimation of creatinine clearance when urine cannot be collected. Lancet (1971) 1.61
Childhood tuberculosis. A diagnostic dilemma. Chest (1993) 1.61
Incidence of hepatotoxicity in children receiving isoniazid chemoprophylaxis. Pediatr Infect Dis J (1989) 1.56
Cdk2-dependent phosphorylation of p27 facilitates its Myc-induced release from cyclin E/cdk2 complexes. Oncogene (1997) 1.54
Malabsorption of antimycobacterial medications. N Engl J Med (1993) 1.53
Evaluation of method for secondary DNA typing of Mycobacterium tuberculosis with pTBN12 in epidemiologic study of tuberculosis. J Clin Microbiol (1996) 1.52
Antibiotic tissue penetration and its relevance: models of tissue penetration and their meaning. Antimicrob Agents Chemother (1991) 1.52
Antibiotic tissue penetration and its relevance: impact of tissue penetration on infection response. Antimicrob Agents Chemother (1991) 1.50
Failure of traditional trough levels to predict tacrolimus concentrations. Ther Drug Monit (2001) 1.50
Experience with flexible fiberoptic bronchoscopy with bronchoalveolar lavage as a diagnostic tool in children with AIDS. Am J Dis Child (1992) 1.47
Modulation of cyclin gene expression by adenovirus E1A in a cell line with E1A-dependent conditional proliferation. J Virol (1994) 1.46
Malabsorption of antituberculosis medications by a patient with AIDS. N Engl J Med (1992) 1.45
Estrogen-induced pancreatitis in patients with previously covert familial type V hyperlipoproteinemia. Metabolism (1972) 1.39
A nomogram for digoxin therapy. Am J Med (1974) 1.38
Interactions between synaptic vesicle fusion proteins explored by atomic force microscopy. Proc Natl Acad Sci U S A (2003) 1.36
Streptomyces pneumonia in a patient with human immunodeficiency virus infection: case report and review of the literature on invasive streptomyces infections. Clin Infect Dis (1998) 1.31
Reducation of digitalis toxicity by computer-assisted glycoside dosage regimens. Ann Intern Med (1972) 1.30
Neonatal familial type II hyperlipoproteinemia: cord blood cholesterol in 1800 births. Metabolism (1971) 1.23
Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers. Clin Pharmacol Ther (2012) 1.23
Patient access to the medical record: a study of physician attitudes. Med Rec News (1978) 1.22
Pharmacokinetics of ethambutol under fasting conditions, with food, and with antacids. Antimicrob Agents Chemother (1999) 1.21
Pharmacokinetics of amphotericin B in infants and children. J Infect Dis (1987) 1.21
Failure of drug penetration and acquisition of drug resistance in chronic tuberculous empyema. Tuber Lung Dis (1995) 1.16
Preliminary assessment of three-dimensional magnetic resonance imaging for various colonic disorders. Lancet (1997) 1.16
Syntaxin 13 is a developmentally regulated SNARE involved in neurite outgrowth and endosomal trafficking. Eur J Neurosci (2000) 1.15
Diagnosis of tuberculosis in children: increased need for better methods. Emerg Infect Dis (1996) 1.15
Early bactericidal activity of isoniazid in pulmonary tuberculosis. Optimization of methodology. The DATRI 008 Study Group. Am J Respir Crit Care Med (1997) 1.13
Detection of mass lesions with MR colonography: preliminary report. Radiology (1998) 1.13
Application of a Bayesian method to monitor and adjust vancomycin dosage regimens. Antimicrob Agents Chemother (1990) 1.13
Detection of Mycobacterium tuberculosis in clinical specimens from children using a polymerase chain reaction. Pediatrics (1996) 1.12
Vitamin D, race, and experimental pain sensitivity in older adults with knee osteoarthritis. Arthritis Rheum (2012) 1.12
Clinical studies with computer-assisted initial lidocaine therapy. Arch Intern Med (1984) 1.11
Effect of transfusion in acute chest syndrome of sickle cell disease. J Pediatr (1995) 1.10
Congenital tuberculosis presenting as sepsis syndrome: case report and review of the literature. Pediatr Infect Dis J (2001) 1.09
Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens. Bone Marrow Transplant (2001) 1.06
Low serum levels of oral antimycobacterial agents in patients with disseminated Mycobacterium avium complex disease. J Infect Dis (1993) 1.06
Drug-drug interactions in inmates treated for human immunodeficiency virus and Mycobacterium tuberculosis infection or disease: an institutional tuberculosis outbreak. Clin Infect Dis (2002) 1.06
Persistent postpneumonic pneumatoceles in children. Chest (1981) 1.06
Familial combined hyperlipoproteinemia: studies in 91 adults and 95 children from 33 kindreds. Metabolism (1973) 1.05
Primary drug-resistant tuberculosis. Report of an outbreak. N Engl J Med (1970) 1.05
Successful treatment of vancomycin-resistant Enterococcus faecium meningitis with linezolid: case report and literature review. Scand J Infect Dis (2001) 1.05
Tuberculosis and pregnancy. Clin Chest Med (1992) 1.05
Clinical and public health aspects of tuberculous meningitis in children. J Pediatr (1995) 1.04
Primary drug-resistant tuberculosis in children. Emergence of primary drug-resistant strains of M. tuberculosis to rifampin. Am Rev Respir Dis (1986) 1.03
Population pharmacokinetics of ethionamide in patients with tuberculosis. Tuberculosis (Edinb) (2002) 1.02
Tuberculous osteomyelitis of the long bones in children. Pediatr Infect Dis J (1995) 1.02
Population pharmacokinetic models: effect of explicit versus assumed constant serum concentration assay error patterns upon parameter values of gentamicin in infants on and off extracorporeal membrane oxygenation. Ther Drug Monit (1994) 1.01
Gentamicin population pharmacokinetic models for low birth weight infants using a new nonparametric method. Clin Pharmacol Ther (1991) 1.01
Imipenem pharmacokinetics in patients with burns. Clin Pharmacol Ther (1990) 1.01
Universal screening for tuberculosis infection. School's out! JAMA (1995) 1.00
Nontuberculous mycobacterial infections of the head and neck. Arch Otolaryngol Head Neck Surg (1994) 1.00
Miliary tuberculosis in two infants after nursery exposure: epidemiologic, clinical, and laboratory findings. Am Rev Respir Dis (1976) 0.99
Anterior uveitis and hypotony after intravenous cidofovir for the treatment of cytomegalovirus retinitis. Ophthalmology (1998) 0.99
Absence of rearrangements in the tumour susceptibility gene TSG101 in human breast cancer. Nat Genet (1997) 0.99
Phthisiology at the dawn of the new century. Chest (2000) 0.98
Different distributions of lung and blood lymphocyte subsets in pediatric AIDS or tuberculosis. Ann Clin Lab Sci (1993) 0.98
Ofloxacin population pharmacokinetics in patients with tuberculosis. Int J Tuberc Lung Dis (2002) 0.97
Bronchiectasis in pediatric AIDS. Chest (1997) 0.96
Musculoskeletal disorders associated with type-IV hyperlipoproteinaemia. Lancet (1972) 0.96
Comparisons between antimicrobial pharmacodynamic indices and bacterial killing as described by using the Zhi model. Antimicrob Agents Chemother (1998) 0.96